CRBP
Corbus Pharmaceuticals Holdings, Inc.Healthcare · $82M market cap
Verdict
We can't put a fair value on CRBP right now. It has lost money in each of its last 3 years, and our valuation needs recent profits to project from.
Business quality
1 of 5 clear the 10% bar. What are the Big Five?
Follow CRBP
Track it on your watchlist and see the full analysis. Free.
Create a free accountInsider activity
Since Oct 29, 2026: no open-market purchases and 3 sales worth $5.2M. Why purchases matter
Sales
Questions about CRBP
Are insiders buying CRBP?
Since Oct 29, 2026: no open-market purchases and 3 sales worth $5.2M.
How can I check CRBP's value myself?
Use the free Sticker Price calculator, already filled with CRBP's numbers. Change the growth, P/E or required return and see what you'd pay. Open the calculator →
Similar stocks · Biotechnology
About Corbus Pharmaceuticals Holdings, Inc.
Corbus Pharmaceuticals Holdings, Inc. is an oncology company, which engages in research, development, and commercializing therapeutics for cancer and obesity. Its pipeline includes CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFß expressed on cancer cells, and CRB-913, a highly peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist for the treatment of obesity. The company was founded in April 2009 and is headquartered in Norwood, MA.
Biotechnology
Fair value and Payback Price are estimates from the company's reported financials, not investment advice. Prices as of Nov 3, 2026. How the Payback Price works